fixyruw.wordpress.com
The 16-week trial gave 159 cancer patientes at 35 sites inthe U.S. and Argentin either one or three milligram dosesof Ostraine, a selectivee androgen receptor modulator. The results show the one milligrak dose gavepatients 0.2 pounds of lean body muscle. The threw milligram dose increased muscle massby 2.9 and 3.3 "Approximately half of all cancer patients suffer from the devastatingh effects of cancer inducee muscle loss,” Adrian an investigator in the clinicakl trial and professor of medicine and oncology at , said in a “Increasing lean body mass may improvs patients' quality of life and even their response to canceer treatment.
” GTx (Nasdaq: GTXI) and MRK) are collaborating to develop Ostrain e as part of a broader program for a new class of drugs with the potentiall to treat musculoskeletal conditions. Shares of Memphis-based GTx, a specialtg pharmaceutical company, closed 32 cents higher Thursdayto $9.30 per share, up 3.44 percent for the day.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment